CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
Gemcitabine, Docetaxel, Capecitabinedrug
Likely dose
Gemcitabine, Docetaxel, Capecitabine 1500mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00996333
NCT00996333Phase 2Completed
CompareCT.gov

Phase II Study of a Biochemically Synergistic Regimen for Metastatic Pancreatic Cancer (Stage IVB) With Gemzar, Taxotere and Xeloda (GTX)

Columbia University·interventional·Posted Oct 16, 2009·Updated Jul 25, 2016

In Brief

A Phase 2 clinical trial evaluating Gemcitabine, Docetaxel, Capecitabine for Metastatic Pancreatic Cancer. Completed, enrolled 46 participants across 1 site.

Detailed Summary

This study is designed to determine whether an investigational drug combination consisting of Gemzar®, Taxotere®, and Xeloda®, (called GTX) is safe and effective in treating advanced pancreatic cancer and to study and enhance the utility of PET scans in the evaluation of patients with pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Cancer
CountriesUnited States
CollaboratorsSanofi

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 16, 2009
Enrollment StartJun 1, 2003
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 11.3 yearsPosted 16.7 years ago

Interventions

Gemcitabine, Docetaxel, Capecitabinedrug

1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11 This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles.